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Malignant hepatic tumors, including hepatocellular car-
cinoma, cholangiocarcinoma, metastatic carcinoma,
often occur in the elderly population, and the mortality
of the malignancy usually increases with age. However,
one rare hepatic tumor, epithelioid hemangioendothe-
lioma (EHE), is a malignant tumor which primarily
affects middle-aged adults (30–40 years), predomi-
nantly women1. It is a neoplasm of vascular origin with
unknown etiology and has a variable clinical course.
Several cases have been reported in other organs such as
lung, bone marrow, and head and neck, and have been
described by various other names such as intravascular
bronchiolar and alveolar tumor of the lung, sclerosing
angiogenic tumor, sclerosing endothelial tumor, scle-
rosing interstitial vascular tumor, and sclerosing
epithelioid angiosarcoma2–4. Here, we present an el-
derly male patient who was incidentally found to have
this unusual hepatic tumor.
Case Report
A 66-year-old man was hospitalized with a hepatic tumor
discovered incidentally from sonography, which revealed
one hypoechoic lesion of about 3 cm in diameter at the
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S6 segment of the liver. He had chronic hepatitis B with-
out regular follow-up for 10 years. He denied fever,
fatigue, jaundice, abdominal pain, or weight loss. Phys-
ical examination on admission revealed a flat, soft and
non-tender abdomen without hepatosplenomegaly. As-
cites and other stigmata of chronic liver disease were
absent. His aspartate aminotransferase was 63 IU/L
(normal, 5–35 IU/L), alanine aminotransferase 57 IU/L
(normal, 5–30 IU/L), alkaline phosphatase 129 IU/L (nor-
mal, 40–120 IU/L), and total bilirubin 1.1mg/dL (normal,
0.2–1.3 mg/dL). All other results, including complete
blood cell counts, electrolyte concentrations, renal func-
tion and albumin concentration, were within normal
limits. Tumor marker analysis revealed: CA 19-9, 12.18U/
mL (normal, < 30 U/mL); carcinoembryonic antigen,
1.0ng/mL (normal, <5ng/mL); prostate specific antigen,
2.29 ng/mL (normal, < 5.36 ng/mL); and α-fetoprotein
<2.76 ng/mL (normal <6 ng/mL). Abdominal computed
tomography showed a hypoattenuating mass measuring
3 cm in diameter, localized in the S6 segment (Figure
1). It also showed low attenuation in the arterial, por-
tal and late venous phases. Another small nodule was
found in the right lower lung field. Chest computed
tomography revealed multiple, small, well-defined nod-
ules scattered throughout the periphery of both lungs
(Figure 2). Echo-guided biopsy of the hepatic tumor
revealed EHE in portal areas mixed with benign hepa-
tocytes. The tumor cells revealed epithelioid pink cyto-
plasm and some contained cytoplasmic red blood cells
(Figure 3). The tumor stains were positive for vimentin,
CD34, CD31, and factor VIII related-antigen (Figure 4).
Because of the diagnosis of hepatic EHE with pul-
monary metastasis, the patient was started on combi-
nation chemotherapy comprising cisplatin (50 mg/m2),
doxorubicin (50mg/m2) and cyclophosphamide (500mg/
m2), all given on day 1 and repeated every 21 days. A
total of six cycles of chemotherapy was given, and re-
peated computed tomography of the thorax and whole
abdomen showed no difference in the nodules. During
the 17 months after the last course of chemotherapy,
he did not suffer from any discomfort.
Discussion
The term epithelioid hemangioendothelioma was first
described as a distinct entity by Weiss and Enzinger 
in 1982, for a group of 41 soft-tissue vascular tumors 
of endothelial origin, with unpredictable malignant
Figure 1. Abdominal computed tomography revealing a
hypoattenuating mass measuring 3 cm in diameter localized
in the S6 segment.
Figure 2. Chest computed tomography revealing multiple,
small, well-defined nodules scattered throughout the
periphery of both lungs.
Figure 3. Echo-guided biopsy revealing the tumor cells with
epithelioid pink cytoplasm and some containing cytoplas-
mic red blood cells (hematoxylin and eosin, 40×).
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potential and intermediate histologic characteristics
between hemangioma and angiosarcoma1,3–6. However,
primary malignant hepatic EHE is a rare tumor with
an incidence of < 0.1 per 100,000 population and was
reported first in 1984 by Ishak et al. in a series of 32
patients1,3,4,6,7. It has a variable natural course, ranging
from a favorable disease with prolonged survival, even
without therapy, to a rapidly progressive disease with a
fatal outcome1,4,5,7. In the largest reported series of 137
cases of liver EHE from the Armed Forces Institute of
Pathology5, the patients ranged in age from 12 to 86
years (median, 46 years) with 61% female and 39% male.
In another review of published reports of 434 patients3,
the mean age was 41.7 years and female predominance
(57.6%) was found. However, there was no significant dif-
ference in incidence between men (n = 16) and women
(n=18) of a 34-patient case study in Japan6. This might
be attributed to the increased use of oral contraceptives
in other countries apart from Japan, which has govern-
mental legal limitations on the use of such agents.
The clinical manifestations of hepatic EHE are non-
specific, and most are asymptomatic. Among sympto-
matic patients, the most common symptom was right
upper quadrant pain3–5,8. Other symptoms are un-
common and include jaundice, weight loss, fatigue,
ascites, hepatomegaly, and fever2,4,5. The etiologic 
factors are not yet clear1–5,7,9, and some investigators
have suggested an association with oral contracep-
tives, whereas others have noted an association with
exposure to vinyl chloride, asbestos, thorotrast, major
trauma to the liver, viral hepatitis, primary biliary cir-
rhosis, and alcohol consumption1,3,4,10. However, hepatic
EHE does not occur on a background of chronic liver
disease or hepatitis, such as other types of tumors. In
our patient, the only risk factor may be chronic hepa-
titis B, but it is an unclear one on current knowledge.
In one reviewed report of 127 previously published
cases4, no positive correlation between EHE of the
liver and any form of hepatitis could be confirmed.
Only a few patients had positive results for hepatitis B
surface antibody (5.6%), hepatitis B core antigen
(11.5%), and hepatitis B surface antibody (11.5%). Two
patients were found to have hepatitis C.
No reliable parameters, including tumor markers or
imaging studies, have been identified to predict the bio-
logic behavior3,7,9; therefore, the tumor is often misdi-
agnosed because of the pleomorphism of the tumor cells,
together with the varied pattern of the tumors, as well
as the parenchymal and stromal reactions. Approximately
60–80% of patients are initially misdiagnosed as hav-
ing cholangiocarcinoma, angiosarcoma, hepatocellular
carcinoma, metastatic carcinoma, or sclerosing heman-
gioma1–4. In the 137-patient case series, most patients
(82%) had multiple liver nodules generally in both
lobes which differed greatly in size (0.2–14 cm)2,5. In a
review of the literature of 434 patients3, 87% presented
with a multifocal tumor which involved both liver lobes,
whereas only 13% had a unifocal tumor. The right lobe
was affected more than the left lobe in both multifocal
and unifocal presentations. Thus, the correct diagnosis
can be signaled by certain features1,7: the occurrence
in young adults; the presence of numerous intrahepatic
tumors, yet a good clinical condition; the slow course
of the disease; and the presence of intratumoral calci-
fications, an inconsistent but suggestive feature.
However, our patient did not have the above features.
There are several diagnostic difficulties9. First, the
presentation is nonspecific; second, liver function tests
may not become abnormal until the disease is advanced;
third, ultrasound scans of the liver can be inconclu-
sive; and, finally, computed tomography may lead to a
misdiagnosis of metastatic disease because of the
tumor’s multifocal nature. So the definitive diagnosis
requires immunohistochemical evidence of endothe-
lial differentiation1–4,7,10, which is demonstrated by the
presence of factor VIII-related antigen and cytokeratins,
as in our case. Microscopically, these tumors have cen-
tral densely sclerotic, hypocellular myxoid areas or
occasional necrosis and peripheral cellular regions of
epithelioid and/or dendritic cells. The tumor may extend
along the sinusoids and display papillary intravascular
growth into portal and hepatic veins. The epithelioid
cells may have eccentric nuclei with cytoplasmic lumina
Figure 4. Tumor cells strongly immunostained with anti-
body to factor VIII-related antigen (40×).
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containing erythrocytes. The dendritic cells have hyper-
chromatic spindle-shaped nuclei and are found in myx-
oid and sclerotic stroma2,4. Metastases had occurred in
27–28% of patients in previous reports2–4, and have
been described in the lungs, abdominal and mediasti-
nal lymph nodes, spleen, bone, omentum and mesen-
tery, and rarely in the peritoneum, anterior abdominal
wall, thyroid gland, stomach, gallbladder, kidney, and
diaphragm1,3,4. Although simultaneous occurrence of
this tumor in the liver and lungs is a possibility, we
interpret the pulmonary nodules in this case as metas-
tases based on the large size of the hepatic tumor.
The management of hepatic EHE has been liver
resection, liver transplantation, no treatment, chemo-
therapy, radiotherapy, and transcatheter arterial embo-
lization1–4,7. Because of the rarity of this tumor and its
unpredictable natural history, it is impossible to assess
the effectiveness of these therapies. Only retrospective
studies and a review of the literature offer adequate
information. Among these therapeutic modalities, liver
resection has been the treatment of choice in patients
with resectable EHE, resulting in prolonged survival1,2.
However, surgical resection is often impossible, owing
to the frequent multicentric origin of the tumor1,4.
Orthotopic liver transplantation has been proposed as
the treatment of choice because of the hepatic multi-
centricity of the tumor, especially because it affects
young adults who are usually in good physical condi-
tion; this is also an acceptable option for patients who
have extrahepatic manifestations2,3. Some patients sur-
vive for a long time despite no treatment, as reported
in a few reports3,4. In addition, one 75-year-old woman
had complete spontaneous regression of hepatic EHE
within a 20-month period8. However, it has been impos-
sible to predict hepatic EHE reliably in patients with non-
aggressive tumors until now and to consider them for 
“no treatment” and a “wait-and-see” strategy. Although
chemotherapy and radiotherapy have been used, it is
not possible to assess their effectiveness because of the
variable natural history of hepatic EHE and lack of pro-
spectively collected data. Thus, the role of different adju-
vant therapies for patients remains to be determined3,4,8.
Our patient was treated with doxorubicin, cisplatin and
cyclophosphamide; he had stable disease all through
follow-up, but this might be a result of the highly indo-
lent course of the disease. Transcatheter arterial em-
bolization was reported as having a short-term benefit in
a few cases4; however, the number of patients was too
small to estimate the benefit of this form of treatment.
Hepatic EHE is a rare tumor which primarily affects
middle-aged adults (30–40 years), especially women. A
smattering of cases still occur in the elderly, and con-
current multiorgan involvement has been noted. It
has a variable natural course and nonspecific clinical
manifestations, which may mimic metastatic hepatic
tumors. No reliable parameters, including tumor mark-
ers or imaging studies, have been identified. The only
definitive diagnosis requires immunohistochemical
evidence of endothelial differentiation, which is demon-
strated by the presence of factor VIII-related antigen
and cytokeratins. In addition, liver resection has been
the treatment of choice in patients with resectable
EHE, resulting in prolonged survival. Thus, this rare
hepatic tumor should be considered in the differential
diagnosis of hepatic tumors in the elderly.
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